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Protein Kinase C Isoforms Have Differential Roles
in the Regulation of Human Sebocyte Biology
Tama´s Ge´czy1, Attila Ola´h1, Bala´zs I. To´th1, Gabriella Czifra1, Attila G. Szo¨llo*si1, Tama´s Szabo´2,
Christos C. Zouboulis3, Ralf Paus4,5 and Tama´s Bı´ro´1
Protein kinase C (PKC) isoforms have crucial roles in cutaneous signaling. Interestingly, we lack information
about their involvement in human sebaceous gland biology. Therefore, in this current study, we investigated the
functions of the PKC system in human immortalized SZ95 sebocytes. Using molecular biological approaches,
imaging, and functional assays, we report that SZ95 sebocytes express the conventional cPKCa; the novel
nPKCd, e, and Z; and the atypical aPKCz. Activation of the PKC system by phorbol 12-myristate 13-acetate (PMA)
stimulated lipid synthesis (a hallmark of differentiation) and resulted in translocation and then downregulation
of cPKCa and nPKCd. In good accord with these findings, the effect of PMA was effectively abrogated by
inhibitors and short interfering RNA-mediated ‘‘silencing’’ of cPKCa and nPKCd. Of further importance,
molecular or pharmacological inhibition of nPKCd also prevented the lipogenic and apoptosis-promoting
action of arachidonic acid. Finally, we also found that ‘‘knockdown’’ of the endogenous aPKCz activity markedly
increased basal lipid synthesis and apoptosis, suggesting its constitutive activity in suppressing these processes.
Collectively, our findings strongly argue for the fact that certain PKCs have pivotal, isoform-specific, differential,
and antagonistic roles in the regulation of human sebaceous gland–derived sebocyte biology.
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INTRODUCTION
Protein kinase C (PKC) comprises a family of serine/threonine
kinases (Nishizuka, 1988, 1992) that have crucial roles in the
regulation of various biological mechanisms including, e.g.,
cell growth, differentiation, and survival. The PKC family
includes the following: (i) calcium- and diacylglycerol- or
phorbol ester-dependent ‘‘conventional’’ isoforms (PKCa, bI,
bII, and g; cPKCs); (ii) calcium-independent ‘‘novel’’ nPKCs
(PKCd, e, Z, and y); and (iii) calcium- and phorbol ester-
independent ‘‘atypical’’ aPKCs (PKCz and l/i). These
isoenzymes possess a characteristic expression pattern in a
given tissue and cell type, and differentially regulate numer-
ous cellular processes in an isoenzyme-specific manner
(Gould and Newton, 2008; Reyland, 2009; Newton, 2010;
Rosse et al., 2010).
Emerging evidence suggests a pivotal role of the PKC
system in cutaneous biology (Denning, 2004; Breitkreutz
et al., 2007). Indeed, PKC activity has been shown to
modulate the proliferation and differentiation of epidermal
keratinocytes (Lee et al., 1998; Papp et al., 2003). In addition,
isoenzyme-specific roles of PKCs expressed by keratinocytes
have also been reported; i.e., cPKCa and nPKCd were found
to be key components in stimulating epidermal differen-
tiation, whereas PKCe was shown to promote skin tumor
development (Lee et al., 1997; Li et al., 1999a; Jansen et al.,
2001; Neill et al., 2003; Papp et al., 2004).
Importantly, PKCs are also involved in controlling hair
growth and cycling. Several PKC isoforms (e.g., cPKCa and
b and nPKCd and e) were shown to be expressed in various
compartments (e.g., outer root sheath keratinocytes, dermal
papilla) of the hair follicle (Eicheler et al., 1997; Li et al., 2003;
Neill et al., 2003). Moreover, levels of certain isoforms
appeared to alter with the hair cycle; e.g., expression of cPKCa
showed good correlation with increasing hair growth (anagen)
in various mouse models (Li et al., 1999b, 2003). Of further
importance, modification of PKC activity by either phorbol
esters or synthetic inhibitors resulted in profound alterations in
human hair shaft elongation, as well as dermal papilla fibroblast
growth and survival (Harmon et al., 1995; Ferraris et al., 1997).
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Intriguingly, we lack data on the functional role of the PKC
system in the other component of the human pilosebaceous
unit, i.e., the sebaceous gland and its sebocytes. Sebocytes,
engaged in holocrine (sebum) secretion, are a major site of
hormone synthesis and metabolism in the human skin, and
possess numerous ionotropic, metabotropic, and nuclear
receptor–coupled pathways (Zouboulis et al., 2002; Zoubou-
lis and Bohm, 2004; Alestas et al., 2006; Zhang et al., 2006;
Dobrosi et al., 2008; To´th et al., 2009, 2011), which may all
function as potential regulators of PKCs. Hence, sebocytes
provide a highly instructive research tool for exploring PKC
functions, which promises additional sets of information that
may complement those obtainable with human hair follicle
and with other extrafollicular cell types of the human skin.
Therefore, in this study, we identified and investigated
members of the PKC system in SZ95 sebocytes—a human
sebaceous gland-derived immortalized cell line that possesses
striking functional similarities to those of primary human
sebocytes (Zouboulis et al., 1999)—and dissected their
isoform-specific role in the regulation of sebocyte biology.
RESULTS
Human SZ95 sebocytes possess a characteristic PKC isoform
pattern
We first investigated the presence of PKC isoforms in SZ95
sebocytes. Using immunocytochemistry, western blotting,
and quantitative ‘‘real-time’’ PCR, we provide the first
evidence that SZ95 cells express cPKCa; nPKCd, e, and Z;
and aPKCz (Figure 1a and b). Importantly, none of the above
techniques identified other members of the family (i.e.,
cPKCbI, bII, and g; nPKCZ and y; aPKCl/i; and the unique
PKCm-PKD) (data not shown). In addition, quantitative
real-time PCR also revealed that, among the above isoforms,
cPKCa, nPKCd, and aPKCz exhibited the highest expressions,
whereas the levels of nPKCe and Z were rather low
(Figure 1b).
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Figure 1. Human SZ95 sebocytes possess a characteristic protein kinase C (PKC) isoform pattern. (a) Specific immunoreactivity of various PKC isoforms
as determined by immunofluorescence (FITC, green fluorescence). NC, negative control obtained after omitting the primary antibody. Nuclei were
counterstained with 40,6-diamidino-2-phenylindole (DAPI) (blue fluorescence). Bars¼ 20mm. Insets: Expressions of PKC isoforms were also determined
in cell lysates of SZ95 sebocytes by western blot analysis. (b) Quantitative ‘‘real-time’’ PCR (Q-PCR) analysis of mRNA transcript expression profile of the
PKC isoenzymes. Data (mean±SEM) are expressed as a fraction of the mean value of expression of the housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (defined as 1). Two additional experiments yielded similar results. aPKC, atypical PKC; cPKC, conventional PKC; nPKC, novel PKC.
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Pharmacological modulation of PKC activity alters lipid
synthesis but does not influence cell viability of SZ95 sebocytes
One of the main hallmarks of sebocyte differentiation is
the synthesis of various lipids, among which neutral lipids
represent a major component (Rosenfield, 1989; Thody and
Shuster, 1989; Doran et al., 1991; Zouboulis et al., 1998).
Therefore, we investigated the effects of PKC-acting agents on
the lipid content of cultured SZ95 sebocytes. Nile Red
staining–based quantitative Fluorescence Image Plate Reader
(FLIPR) measurement revealed that treatment with the
general PKC activator phorbol 12-myristate 13-acetate (PMA)
(up to 48 hours) significantly stimulated lipid synthesis in a
dose-dependent manner (Figure 2a). This effect was equally
inhibited by GF109203X (inhibitor of cPKCs and nPKCs),
Go¨6976 (inhibitor of cPKCs), and Rottlerin (inhibitor of
nPKCd) (Figure 2b). It is noteworthy that none of the inhibitors
alone (i.e., when applied without PMA) affected basal lipid
content of the cells (Figure 2b). Furthermore, none of the
above protocols altered cell viability or induced cell death of
any form (apoptosis, necrosis); namely, the PKC activator
or the inhibitors did not significantly modify the viable
cell number (MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide)-based colorimetric proliferation assay;
Figure 2c), nor did they induce necrotic (SYTOX Green
accumulation assay) or apoptotic cell death (fluorimetric
measurement of the decrease of mitochondrial membrane
potential—DilC1(5) labeling) (Figure 2d).
The ability of PMA to stimulate lipid synthesis of SZ95
sebocytes is mediated by cPKCa and nPKCd
The above results suggested the involvement of multiple PKC
isoforms in the action of PMA. However, numerous reports
indicate that the above inhibitors may often target other
signaling molecules (Gschwendt et al., 1994; Alessi, 1997),
which question their specificity and/or selectivity for the PKC
isoforms. Therefore, in order to define the specific roles of the
PKC isoenzymes that were expressed at the highest levels
(i.e., cPKCa, nPKCd, and aPKCz) in mediating the lipid
synthesis–stimulating effect of PMA, we have carried out a
series of cellular imaging and molecular biology experiments.
Activation of a given PKC isoform is accompanied by the
translocation of the molecule to another cellular compart-
ment. Therefore, we first investigated the potential alteration
in the subcellular localization of PKCs upon short-term
(1 hour) PMA treatment. As revealed by immunostaining of
PKCs followed by confocal microscopy analysis, 10 nM PMA
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Figure 2. Phorbol 12-myristate 13-acetate (PMA) treatment stimulates lipid synthesis of SZ95 sebocytes. Cells were treated with vehicle (Control, C);
the protein kinase C (PKC) activator PMA (at the indicated doses); the PKC inhibitors GF109203X (GF), Go¨6986 (Go¨), and Rottlerin (Rottl.) at 10 nM; or
combinations for 48 hours. (a, b) Quantitative measurement of lipids as assessed by Nile Red labeling, followed by Fluorescence Image Plate Reader
(FLIPR) measurement. Neutral lipids indicate de novo-synthesized intracellular lipids. (c) Determination of cell viability by colorimetric MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. (d) Assessment of apoptosis by fluorimetric DilC1(5) assay reflecting mitochondrial membrane
potential, and of necrosis by fluorimetric SYTOX Green assay reflecting ruptured cell membrane. Data (mean±SEM) are expressed as a percentage of the
mean value of the vehicle-treated control group (defined as 100%, solid line). *Marks significant (Po0.05) differences compared with the control group.
In panel b, #marks significant (Po0.05) differences compared with the PMA-treated group; n¼4 in each group. Three or four additional experiments yielded
similar results.
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induced the translocation of cPKCa and nPKCd. As expected,
being a PMA-insensitive isoform, the subcellular localization
of aPKCz was not changed upon the application of the
phorbol ester (Figure 3a).
Prolonged activation of the PKC isoforms results in the
cleavage of the molecule by proteases, resulting in a
decreased expression of the given PKC (downregulation).
Therefore, we also assessed the effect of long-term (up to 3
days) PMA administration on the levels of the PKCs.
Consistent with the above confocal microscopy data, as
revealed by western blot analysis, the phorbol ester markedly
downregulated cPKCa and nPKCd, whereas the level of
aPKCz was not altered (Figure 3b). Loading controls are
presented in Supplementary Figure S1a online.
The involvement of cPKCa and nPKCd in mediating the
cellular effects of PMA was further assessed by short
interfering RNA (siRNA) technique. Western blot analysis
demonstrated that the expressions of ‘‘targeted’’ PKC isoforms
were significantly ‘‘knocked down’’ by the specific siRNA
probes at day 2 after transfection and remained suppressed on
a
b Control
1
100 100 100 122 93 91 36.4 5.9 4.3
76.5 61.8 24.4 59.9 3.5 2.6
103 107 87.3 92.4 104 91.6
100 100 100
100 100 100
OD (%)
OD (%)
~80 kDa
~80 kDa
OD (%)
~70 kDa
Days in culture:
cPKCα
nPKCδ
aPKCζ
2 3 1 2 3 1 2 3
AA 50 μM PMA 10 nM
cPKCα
nPKCδ
aPKCζ
PMAControl AA
Figure 3. Phorbol 12-myristate 13-acetate (PMA) and arachidonic acid (AA) differentially translocate and downregulate certain protein kinase C (PKC)
isoforms in SZ95 sebocytes. Cells were treated with vehicle (Control), 10 nM PMA, and 50 mM AA for 1 hour (a) to assess translocation, or for 1–3 days
(b) to measure downregulation of PKC isoforms. (a) Immunofluorescence labeling (FITC, green fluorescence) of PKCs followed by confocal microscopy analysis.
Arrows indicate translocation. Bars¼ 20 mm. (b) Western blot analysis. The amounts of the individual PKC isoforms were quantified by densitometry
(optical density, OD) and expressed as the percentage of the value of immunoreactive bands of daily-matched control group regarded as 100%. Note the
translocation and downregulation of conventional PKCa (cPKCa) and novel PKCd (nPKCd) by PMA, and of nPKCd by AA. Three additional experiments
yielded similar results. aPKC, atypical PKC.
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day 3 as well (Figure 4a–c). Specificity and selectivity of the
procedure were demonstrated by the following: (i) siRNA-
mediated silencing of given isoforms did not affect the
expression of the other two PKCs investigated (Figure 4a and
b); (ii) scrambled siRNA probes had no effect on the
expression of the PKC isoforms (Figure 4a–c). Additional
loading controls are presented in Supplementary Figure S1b
online.
Silencing of cPKCa and nPKCd did not modify the basal
lipid synthesis (Figure 4d) and did not induce apoptosis/
necrosis (Figure 4e) in SZ95 sebocytes. However, in good
accord with the above data, ‘‘knockdown’’ of either of these
isoforms significantly reduced the action of PMA to promote
lipid synthesis (Figure 4d). Intriguingly, the siRNA-mediated
silencing of aPKCz markedly increased the basal lipid
synthesis of the sebocytes (Figure 4d) and, furthermore,
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Figure 4. Conventional protein kinase Ca (cPKCa) and novel protein kinase Cd (nPKCd) are involved in mediating the lipogenic action of phorbol
12-myristate 13-acetate (PMA), whereas short interfering RNA (siRNA)-mediated ‘‘silencing’’ of atypical protein kinase Cf (aPKCf) induces lipid synthesis
and apoptosis in SZ95 sebocytes. Various siRNA probes against PKC isoforms, as well as a scrambled siRNA probe (Scr. si), were introduced into cells by
transfection. To evaluate the efficacy of this intervention, at days 1–4 after transfection, cells were subjected to western blot (WB) analysis. As controls (C),
the effect of the transfection reagent was determined. As a housekeeping molecule, expression of cytochrome-C (Cyt-C) was assessed. (a, b) Representative
WB data at (a) days 1–4 and at (b) day 2 after transfection. (c) Statistical analysis of WB data. Optical density (OD) values of specific immunosignals were
determined at day 2 after transfection in three independent experiments. Normalized OD values (to Cyt-C) in each group were then averaged and expressed
as mean±SEM, as the percentage of the averaged values of the control groups was regarded as 100%. *Marks significant (Po0.05) differences compared
with the Scr. si groups. At day 2 after transfection, cells were treated with 10 nM PMA for 48 hours. (d) Determination of neutral lipids as assessed by
Nile Red labeling followed by Fluorescence Image Plate Reader (FLIPR) measurement. (e) Determination of cell viability by colorimetric MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, of apoptosis by fluorimetric DilC1(5) assay, and of necrosis by fluorimetric SYTOX
Green assay. Data (mean±SEM) of three independent experiments are expressed as a percentage of the mean value of the Scr. si group (defined as 100%,
solid line). *Marks significant (Po0.05) differences compared with the Scr. si group, whereas #marks significant (Po0.05) differences compared with the
PMA-treated group; n¼ 4 in each group. The Scr. si group displayed no significant difference compared with the non-transfected SZ95 sebocyte population
subjected to identical treatment protocols (data not shown).
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suppressed cellular viability and induced apoptosis (but not
necrosis) (Figure 4e). Of further importance, elevation of
basal lipid content was so marked in the aPKCz knocked-
down cells that PMA was unable to further stimulate lipid
accumulation (Figure 4d).
The ability of arachidonic acid to stimulate lipid synthesis
and induce apoptosis of SZ95 sebocytes are selectively
mediated by nPKCd
The above-mentioned effects of PMA strikingly resembled the
previously described findings with arachidonic acid (AA), one
of the most effective inducers of lipid synthesis in SZ95
sebocytes (Wro´bel et al., 2003; Alestas et al., 2006; To´th
et al., 2009). Therefore, we wished to dissect whether or not
the PKC isoforms are also involved in mediating the cellular
effect of AA. As expected, AA induced a marked lipid
synthesis in SZ95 sebocytes (Figure 5a). This effect was signi-
ficantly (yet only partially) abrogated by both GF109203X
and Rottlerin but not by Go¨6976 (Figure 5a), suggesting that
cPKCa most probably does not participate in mediating the
effect of AA. Furthermore, PMA was able to further increase
the lipid synthesis in the AA-treated cells (Figure 5a).
Our previous studies have also shown that the effect
of AA to augment lipid synthesis in SZ95 sebocytes was
accompanied by the induction of sebocyte apoptosis (Wro´bel
et al., 2003; To´th et al., 2009). Therefore, we investigated the
involvement of the PKC system in the AA-induced apoptotic
process. As expected, AA induced apoptosis (fluorimetric
measurement of mitochondrial membrane potential) but
not necrosis (SYTOX Green accumulation assay) in SZ95
sebocytes (Figure 5b). This effect of AA was almost
completely prevented by GF109203X and Rottlerin but not
by Go¨6976, similar to the actions of these inhibitors on the
AA-induced lipid synthesis. Finally, we found that the PKC
activator PMA did not modify the effect of AA to promote
apoptosis (Figure 5b).
Next, using the cellular and molecular approaches
mentioned above, we further investigated the isoform-
selective involvement of certain PKCs in the action of AA.
Confocal microscopy analysis revealed that a short-term AA
treatment (1 hour) of SZ95 sebocytes selectively translocated
nPKCd, whereas it did not modify the subcellular localiza-
tions of cPKCa and aPKCz (Figure 3a). Similarly, long-term
(1–3 days) administration of AA selectively downregulated
nPKCd, whereas expressions of the other two isoforms were
insignificantly changed (Figure 3b). In addition, in order to
assess the effect of prolonged AA treatment on cell growth,
proliferation was additionally measured for 3 days. As shown
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Figure 5. The lipogenic and apoptosis-inducing actions of arachidonic acid (AA) are mediated by novel protein kinase Cd (nPKCd) in SZ95 sebocytes.
(a, b) Control or (c, d) short interfering RNA (siRNA)-transfected (2 days after transfection) SZ95 sebocytes were treated with vehicle (Control, C); 10 nM phorbol
12-myristate 13-acetate (PMA); the PKC inhibitors GF109203X (GF), Go¨6976 (Go¨), and Rottlerin (Rottl.) at 10 nM; 50mM AA; or combinations for 48 hours.
(a, c) Quantitative measurement of neutral lipids as assessed by Nile Red labeling, followed by Fluorescence Image Plate Reader (FLIPR) measurement.
(b, d) Assessment of apoptosis by fluorimetric DilC1(5) assay and of (b) necrosis by fluorimetric SYTOX Green assay. Data (mean±SEM) of three independent
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in Supplementary Figure S2 online, long-term application of
AA did not significantly affect the growth rate, suggesting that
the selective downregulation of nPKCd by prolonged AA
application was not due to the suppression in cell number or
selective suppression of viability of those SZ95 sebocytes that
might express nPKCd at high levels.
Moreover, the effect of AA to stimulate lipid synthesis and
induce apoptosis was significantly suppressed in those SZ95
sebocytes in which the expression of nPKCd (but, notably, not
that of cPKCa) was silenced by siRNA (Figure 5c and d). In
aPKCz-silenced sebocytes, AA was able to further stimulate
the already highly elevated (basal) lipid synthesis; however,
in these cells, the apoptosis was so marked (and hence the
mitochondrial membrane potential was so reduced) that the
effect of AA to induce further apoptosis was not measurable
(Figure 5c and d). Nevertheless, these findings collectively
argue for the selective involvement of nPKCd in mediating the
cellular effects of AA.
DISCUSSION
In this study, we report that human sebaceous gland–derived
SZ95 sebocytes possess a characteristic PKC isoform pattern
(i.e., the highly expressed cPKCa, nPKCd, and aPKCz, and the
poorly expressed nPKCe and Z), which is similar to that
described on human epidermal keratinocytes (Lee et al.,
1997, 1998; Papp et al., 2003). In addition, we provide the
first evidence that the highly expressed PKC isoforms have
central (yet differential and antagonistic) roles in regulating
cellular growth, survival, and lipid synthesis of human
sebocytes.
Specifically, we found that the activation of the PKC
system by the phorbol ester PMA-stimulated lipid synthesis.
A series of pharmacological (using various inhibitors)
and molecular biology (using siRNA-mediated ‘‘silencing’’)
studies revealed that this action engaged two isoforms, i.e.,
cPKCa and nPKCd. As these isoenzymes were reported to
stimulate differentiation of human epidermal keratinocytes
(Lee et al., 1997; Li et al., 1999a; Papp et al., 2004), and,
furthermore, as holocrine sebum production is one of the key
hallmarks of sebocyte differentiation (Zouboulis et al., 1999,
2002; Alestas et al., 2006), we can conclude that cPKCa and
nPKCd have key roles in promoting differentiation of these
cutaneous cell types.
Moreover, nPKCd was also involved in selectively
mediating the lipogenic action of AA, one of the most widely
studied inducers of lipid synthesis in SZ95 sebocytes (Wro´bel
et al., 2003; Alestas et al., 2006; Dobrosi et al., 2008; To´th
et al., 2009), which was previously shown to stimulate skin
PKC activity (Reynolds et al., 1993; Lo et al., 1994). Indeed,
both the pharmacological and the molecular inhibition of
nPKCd suspended the lipogenic effect of AA. Of further
importance, in SZ95 sebocytes with ‘‘silenced’’ nPKCd,
AA was unable to induce apoptosis, which suggests the
pro-apoptotic role of nPKCd (in addition to its pro-lipogenic
action). Apparently, cPKCa is not involved in mediating the
actions of AA, because (i) the AA-induced lipid synthesis and
apoptosis was unaltered on sebocytes with ‘‘silenced’’
cPKCa, and (ii) the AA-elevated lipid synthesis (mediated
by nPKCd) was further increased by the coadministration of
PMA, which (besides stimulating nPKCd) additionally acti-
vates cPKCa.
With respect to the potential link between the prosta-
glandin pathways and the action of AA, it should be noted
that sebocytes were found to produce metabolites of both
the lipoxygenase and the cyclooxygenase (COX) pathways
(Alestas et al., 2006). Moreover, it was also shown that
COX inhibitors (indomethacin, diclofenac, etc.) enhanced
sebaceous lipid production (Iwata et al., 2005), whereas the
lipoxygenase inhibitor Zileuton markedly decreased it
(Zouboulis et al., 2005; Zouboulis, 2009). These data suggest
that AA metabolites may have opposite roles in the regulation
of the sebaceous lipid synthesis; i.e., lipoxygenase products
seem to increase sebaceous lipid synthesis, whereas COX
products seem to decrease it. Therefore, the facts that
increased lipid synthesis and apoptotic processes are usually
‘‘walking hand-in-hand’’ during the sebaceous differentiation
and that COX inhibition enhances lipid production make
COX inhibitors very unlikely to decrease AA-induced
apoptosis of the sebocytes. (For our preliminary data on
the effect of AA on immune profile of SZ95 sebocytes,
see Supplementary Figure S3 online and Supplementary
Discussion online.)
Interestingly, neither the siRNA-mediated ‘‘knockdown’’
nor the pharmacological inhibition of cPKCa and nPKCd
resulted in alterations in cellular viability and basal lipid
synthesis of the sebocytes. These data implicate that the
endogenous activities of the two isoforms are not crucial for
regulating basal growth and differentiation of sebocytes.
However, results obtained with PMA and AA strongly suggest
their central involvement in such conditions when the
engagement of various signal-transduction mechanisms
results in production of PKC-activating intracellular second-
ary messengers such as diacylglycerol, Ca2þ , etc. As human
sebocytes express a wide array of metabotropic and nuclear
receptors and their coupled ‘‘lipogenic’’ signaling pathways
(Zouboulis et al., 2002; Zouboulis and Bohm, 2004; Alestas
et al., 2006; Zhang et al., 2006; Dobrosi et al., 2008; To´th
et al., 2009, 2011), it is proposed that cPKCa and/or nPKCd
may have a role in their actions.
The siRNA experiments resulted in other intriguing
findings. Namely, we found a markedly increased lipid
synthesis and apoptosis rate in cells with ‘‘silenced’’ aPKCz
levels. These results, on one hand, suggest that—in contrast
to the pro-lipogenic actions of cPKCa and nPKCd, and the
pro-apoptotic effect of nPKCd—aPKCz rather inhibits lipid
production and apoptosis of SZ95 sebocytes. On the other
hand, our findings also implicate that the endogenous and,
even more importantly, constitutive aPKCz activity is an
indispensible regulatory factor for promoting physiological
sebocyte proliferation and survival.
MATERIALS AND METHODS
Materials
PMA, GF 109203X, and AA were purchased from Sigma-Aldrich
(St Louis, MO). Go¨6976 and Rottlerin were from Calbiochem
(Nottingham, UK). The primary antibodies against cPKCa, bI, bII, g;
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nPKCe and Z; and aPKCz and PKD-PKCm were obtained from
Sigma-Aldrich, and the ones against nPKCd and y and aPKCl/i were
from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culturing
Immortalized human SZ95 sebocytes (derived from facial sebaceous
glands; Zouboulis et al., 1999) were cultured in Sebomed basal
medium (Biochrom, Berlin, Germany) supplemented with 10% fetal
bovine serum (Invitrogen, Paisley, UK), 5 ng ml1 human epidermal
growth factor (Sigma-Aldrich), 1 mM CaCl2, 50 U ml
1 penicillin, and
50 mg ml1 streptomycin (both from Teva, Debrecen, Hungary)
(Dobrosi et al., 2008; To´th et al., 2009).
Western blotting
Immunoblotting was performed to assess the protein expression
of the various PKCs in SZ95 cells. Cell lysates were subjected to
SDS-PAGE (7.5% gels were loaded with 40mg protein per lane),
transferred to BioBond nitrocellulose membranes (Whatman,
Maidstone, UK), and probed with the above-mentioned rabbit
primary antibodies against distinct PKC isoforms (dilution
1:100–1:1,000). Horseradish peroxidase–conjugated rabbit anti-goat
IgG antibody (1:1,000; Bio-Rad, Hercules, CA) was used as a
secondary antibody, and the immunoreactive signal was visualized
by a SuperSignal West Pico Chemiluminescent Substrate enhanced
chemiluminescence kit (Pierce, Rockford, IL) using LAS-3000
Intelligent Dark Box (Fuji, Tokyo, Japan). To confirm equal loading,
membranes were re-probed with an anti-cytochrome-C antibody
(1:50; Santa Cruz). Where indicated, signal intensity was analyzed
with densitometry, using the Image Pro Plus 4.5.0 software (Media
Cybernetics, Silver Spring, MD) (Go¨nczi et al., 2008; Szegedi et al.,
2009).
Immunostaining of PKCs, confocal microscopy
Identification and determination of the subcellular localization of
PKC isozymes in SZ95 cells were carried out by confocal
microscopy following immunolabeling. Cells were fixed in acetone,
permeabilized by 0.1% Triton-X-100 (Sigma-Aldrich), and then
incubated with the above-mentioned rabbit anti-PKC primary
antibodies for 60 minutes (dilution 1:100–1:200). Coverslips were
then stained with an FITC-conjugated secondary antibody (Vector
Laboratories, Burlingame, CA) (dilution 1:200) and examined in a
Zeiss LSM confocal microscopy system (Carl Zeiss, Oberkochen,
Germany) (Bodo´ et al., 2005; Dobrosi et al., 2008; To´th et al., 2009).
Quantitative real-time PCR
Quantitative real-time PCR was carried out on an ABI Prism
7000 sequence detection system (Applied Biosystems, Foster City,
CA) using the 50 nuclease assay. Total RNA was isolated
from cell lysates using TRIzol (Invitrogen). A measure of 3 mg of
total RNA was then reverse-transcribed into cDNA by using 15 U
of AMV reverse transcriptase (Promega, Madison, WI) and
0.025mgml1 oligodT primers (Promega). TaqMan primers and probes
(Applied Biosystems) were applied for subsequent PCR amplification
(assay IDs, Hs00176973_m1 for cPKCa, Hs00176998_m1 for cPKCb,
Hs00177010_m1 for cPKCg, Hs00178914_m1 for nPKCd, Hs00178455_
m1 for nPKCe, Hs00178933_m1 for nPKCZ, Hs00234709_m1 for
nPKCy, Hs00177051_m1for aPKCz, and Hs00702254_s1 for aPKCl/i)
using the TaqMan universal PCR master mix protocol (Applied
Biosystems). As internal controls, transcripts of glyceraldehyde
3-phosphate dehydrogenase were determined (assay ID, Hs99999905_
m1 for human) (Dobrosi et al., 2008; To´th et al., 2009, 2011).
Assessment of viability
Viable cell number was assessed by measuring the ability of
cellular dehydrogenases to convert the tetrazolium salt MTT
(Sigma-Aldrich) to formazan. Cells were plated onto 96-well plates
(Greiner Bio-One, Frickenhausen, Germany) (15,000 cells per well)
in quadruplicates. After treatment, cells were incubated with
0.5 mg ml1 MTT for 3 hours, and the amount of formazan crystals
(generated within the cells) was determined colorimetrically
according to our previous reports (Bodo´ et al., 2005; Kiss et al.,
2008; Szegedi et al., 2009).
Assessment of apoptosis
Reduced mitochondrial membrane potential serves as an early
indicator of the onset of apoptotic processes. SZ95 cells (15,000
cells per well) were plated onto 96-well black-well/clear-bottom
plates (Greiner Bio-One) in quadruplicates. After treatment, their
mitochondrial membrane potential was determined using the
MitoProbe DiIC1(5) Assay Kit (Invitrogen). The fluorescence intensity
(reflecting the level of mitochondrial membrane potential)
was measured on FlexStation II384 FLIPR (Molecular Devices,
San Francisco, CA), as described in our previous reports (Dobrosi
et al., 2008; To´th et al., 2009, 2011).
Assessment of cytotoxicity (necrosis)
The cytotoxic effects of the above PKC-acting reagents were
determined by SYTOX Green labeling (Invitrogen). Ruptured plasma
membranes enable the penetration (and subsequent nucleic acid
binding) of the fluorescent dye into necrotic cells, whereas viable
cells with intact surface membranes display negligible SYTOX Green
uptake. SZ95 cells were plated onto 96-well black-well/clear-bottom
plates (Greiner Bio-One). After treatment, supernatants were
removed and the cells were incubated with a 1mM solution of
SYTOX Green. The fluorescence intensity of the dye was measured
on FLIPR, as described previously (Dobrosi et al., 2008; To´th et al.,
2009, 2011).
Assessment of intracellular lipid content
For a quantitative measurement of the intracytoplasmic lipid
content, Nile Red (Sigma-Aldrich) labeling was used. SZ95 cells
(15,000 cells per well) were plated onto 96-well black-well/clear-
bottom plates (Greiner Bio-One) in quadruplicates. Following
treatment, supernatants were removed from wells and cells were
incubated in 1mg ml1 Nile Red for 20 minutes. The fluorescence
intensity of the dye (excitation: 485 nm; emission: 565 nm) reflecting
the neutral lipid content of intracytoplasmic lipid droplets was
measured on FLIPR (Wro´bel et al., 2003; Alestas et al., 2006;
Dobrosi et al., 2008).
RNA interference (siRNA)
SZ95 sebocytes were seeded on six-well culture plates in medium
lacking antibiotics and were grown until they reached 40–60%
confluence. Cells were then transfected with specific Stealth diRNAi
oligonucleotides (at 40 nM, all from Santa Cruz) against cPKCa
(sc-44227), nPKCd (sc-36253), and aPKCz (sc-29451) using
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Lipofectamine RNAiMAX transfection reagent (Invitrogen). SiRNA-
Negative Control Duplexes (scrambled siRNA) were used as controls
(sc-37007 and sc-44230; Santa Cruz). Immunoblotting was per-
formed daily (for 4 days) to follow the changes in the expression
level of the given PKC isoform after transfection. For subsequent
cellular assays (assessing lipid content, cell viability, apoptosis, and
cytotoxicity) cells were trypsinized 24 hours after transfection,
replated onto 96-well plates, and subjected to the above-mentioned
procedures (Dobrosi et al., 2008; To´th et al., 2009, 2011).
Statistical analysis
When applicable, data were analyzed using a two-tailed unpaired
t-test, and Po0.05 values were regarded as significant differences.
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